Determining Social Risk Factors for Poor Outcomes in Pediatric Cancer Using Children’s Oncology Group Registries |
University of Utah / Anne Kirchhoff, PhD/MPH |
Epidemiology Grants |
2019 |
Utah |
Is SIRT5 a Therapy Target in Acute Lymphoblastic Leukemia? |
University of Utah / Michael Deininger, MD/PhD |
Innovation Grants |
2018 |
Utah |
Role of Primary Cilium Signaling and Dynamics in Medulloblastoma Initiation and Progression |
University of Texas Southwestern Medical Center / Saikat Mukhopadhyay, MD/PhD |
'A' Award Grants |
2016 |
Texas |
RNA Methylation in Metabolically Disrupted Pediatric Cancers |
University of Texas Health Science Center at San Antonio / Patricia Dahia, MD/PhD |
Innovation Grants |
2018 |
Texas |
Mechanisms of LYL1-associated T-ALL development |
Baylor College of Medicine / Margaret Goodell, PhD |
Innovation Grants |
2012 |
Texas |
V alpha-invariant NKT cells as a novel platform for cancer immunotherapy |
Baylor College of Medicine / Leonid Metelitsa, MD, PhD |
Innovation Grants |
2012 |
Texas |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma |
Baylor College of Medicine / Cliona Rooney, PhD |
Reach Grants |
2013 |
Texas |
Validation of microRNAs as valid targets in a pediatric sarcoma |
University of Texas Southwestern Medical Center / Mark Hatley |
Young Investigator Grants |
2011 |
Texas |
Treatment of high-risk pediatric brain tumors with a CD133-targeted adenovirus in combination with temozolomide
|
University of Texas M.D. Anderson Cancer Center / Marta Alonso, PhD |
Young Investigator Grants |
2008 |
Texas |
Natural Killer T cells with an IL-15-armored GD2-specific CAR for Children with Neuroblastoma |
Baylor College of Medicine / Andras Heczey, MD |
Bio-Therapeutic Impact Award |
2017 |
Texas |